Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation

Molecular Cell

Volumn 59, Issue 6, 2015, Pages 904-916

  An, Jian ^a,b,c   Ren, Shancheng ^d   Murphy, Stephen J ^b   Dalangood, Sumiya ^e   Chang, Cunjie ^e   Pang, Xiaodong ^f   Cui, Yangyan ^e   Wang, Liguo ^b   Pan, Yunqian ^a   Zhang, Xiaowei ^a   Zhu, Yasheng ^d   Wang, Chenji ^g   Halling, Geoffrey C ^b   Cheng, Liang ^h   Sukov, William R ^b   Karnes, R Jeffrey ^b   Vasmatzis, George ^b   Zhang, Qing ^e   Zhang, Jun ^b   Cheville, John C ^b   Yan, Jun ^e   Sun, Yinghao ^d   Huang, Haojie ^a,b,c   more..

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e NANJING UNIVERSITY   (China)

^f FUDAN UNIVERSITY   (China)

^g FUDAN UNIVERSITY   (China)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; MESSENGER RNA; ONCOPROTEIN; PROTEASOME; SPOP PROTEIN; TMPRSS2 ERG FUSION PROTEIN; TRANSCRIPTION FACTOR ERG; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ERG PROTEIN, HUMAN; NUCLEAR PROTEIN; PEPTIDE FRAGMENT; PROTEIN BINDING; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IN VITRO STUDY; MALE; MOLECULAR MECHANICS; NONHUMAN; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STEADY STATE; UBIQUITINATION; WILD TYPE; CHROMOSOME BREAKAGE; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR;

AMINO ACID SEQUENCE; CELL PROLIFERATION; CHROMOSOME BREAKPOINTS; HEK293 CELLS; HUMANS; MALE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; REPRESSOR PROTEINS; TRANS-ACTIVATORS; UBIQUITINATION;

EID: 84941792992     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.07.025     Document Type: Article

References (43)

1. An J., Wang C., Deng Y., Yu L., Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014, 6:657-669.
2. Baena E., Shao Z., Linn D.E., Glass K., Hamblen M.J., Fujiwara Y., Kim J., Nguyen M., Zhang X., Godinho F.J., et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013, 27:683-698.
3. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
4. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
5. Blattner M., Lee D.J., O'Reilly C., Park K., MacDonald T.Y., Khani F., Turner K.R., Chiu Y.L., Wild P.J., Dolgalev I., et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 2014, 16:14-20.
6. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P.T., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41:619-624.
7. Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A., Simon J.A., Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 2010, 12:1108-1114.
8. Chen Y., Chi P., Rockowitz S., Iaquinta P.J., Shamu T., Shukla S., Gao D., Sirota I., Carver B.S., Wongvipat J., et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 2013, 19:1023-1029.
9. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., Eeles R., Martin F.L., Phillips D.H., Crundwell M., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
10. Gan W., Dai X., Lunardi A., Li Z., Inuzuka H., Liu P., Varmeh S., Zhang J., Cheng L., Asara J.M., et al. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell 2015, 59:917-930. this issue.
11. Geng C., He B., Xu L., Barbieri C.E., Eedunuri V.K., Chew S.A., Zimmermann M., Bond R., Shou J., Li C., et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. U S A 2013, 110:6997-7002.
12. Geng C., Rajapakshe K., Shah S.S., Shou J., Eedunuri V.K., Foley C., Fiskus W., Rajendran M., Chew S.A., Zimmermann M., et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014, 74:5631-5643.
13. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
14. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
15. Hernández-Muñoz I., Lund A.H., van der Stoop P., Boutsma E., Muijrers I., Verhoeven E., Nusinow D.A., Panning B., Marahrens Y., van Lohuizen M. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl. Acad. Sci. U S A 2005, 102:7635-7640.
16. Huang H., Cheville J.C., Pan Y., Roche P.C., Schmidt L.J., Tindall D.J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 2001, 276:38830-38836.
17. Huang H., Regan K.M., Lou Z., Chen J., Tindall D.J. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006, 314:294-297.
18. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
19. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., Taylor B.S., Sander C., Cardiff R.D., Couto S.S., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41:524-526.
20. Kovtun I.V., Cheville J.C., Murphy S.J., Johnson S.H., Zarei S., Kosari F., Sukov W.R., Karnes R.J., Vasmatzis G. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013, 73:3275-3284.
21. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
22. Kwon J.E., La M., Oh K.H., Oh Y.M., Kim G.R., Seol J.H., Baek S.H., Chiba T., Tanaka K., Bang O.S., et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J. Biol. Chem. 2006, 281:12664-12672.
23. Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., O'Malley B.W. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30:4350-4364.
24. Li G., Ci W., Karmakar S., Chen K., Dhar R., Fan Z., Guo Z., Zhang J., Ke Y., Wang L., et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 2014, 25:455-468.
25. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
26. Liu J., Ghanim M., Xue L., Brown C.D., Iossifov I., Angeletti C., Hua S., Nègre N., Ludwig M., Stricker T., et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009, 323:1218-1222.
27. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., Palanisamy N., Chinnaiyan A.M. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
28. Murphy S.J., Cheville J.C., Zarei S., Johnson S.H., Sikkink R.A., Kosari F., Feldman A.L., Eckloff B.W., Karnes R.J., Vasmatzis G. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012, 19:395-406.
29. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., Suleman K., Varambally S., Brenner J.C., MacDonald T., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
30. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
31. Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161:1215-1228.
32. St.John J., Powell K., Conley-Lacomb M.K., Chinni S.R. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J. Cancer Sci. Ther. 2012, 4:94-101.
33. Theurillat J.P., Udeshi N.D., Errington W.J., Svinkina T., Baca S.C., Pop M., Wild P.J., Blattner M., Groner A.C., Rubin M.A., et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014, 346:85-89.
34. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
35. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
36. Tomlins S.A., Bjartell A., Chinnaiyan A.M., Jenster G., Nam R.K., Rubin M.A., Schalken J.A. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 2009, 56:275-286.
37. Tu J.J., Rohan S., Kao J., Kitabayashi N., Mathew S., Chen Y.T. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 2007, 20:921-928.
38. Wang J., Cai Y., Yu W., Ren C., Spencer D.M., Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008, 68:8516-8524.
39. Wang L., Zeng X., Chen S., Ding L., Zhong J., Zhao J.C., Wang L., Sarver A., Koller A., Zhi J., et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J. 2013, 32:1584-1597.
40. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17:443-454.
41. Zhang Q., Zhang L., Wang B., Ou C.Y., Chien C.T., Jiang J. A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev. Cell 2006, 10:719-729.
42. Zhang H., Pan Y., Zheng L., Choe C., Lindgren B., Jensen E.D., Westendorf J.J., Cheng L., Huang H. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 2011, 71:3257-3267.
43. Zhuang M., Calabrese M.F., Liu J., Waddell M.B., Nourse A., Hammel M., Miller D.J., Walden H., Duda D.M., Seyedin S.N., et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 2009, 36:39-50.